Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 5/20 | 0.35 |
| ▸ | CTSD | P07339 | 2/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581168 | 1.00 | KDM1A (0.42) | KDM1AKDM1BDGAT1BACE1CTSD | |
| SCHEMBL31638339 | 0.92 | KDM1A (0.40) | KDM1AKDM1BDGAT1BACE1CTSD | |
| SCHEMBL21903285 | 0.92 | KDM1A (0.40) | KDM1AKDM1BDGAT1BACE1CTSD | |
| SCHEMBL10155617 | 0.84 | BACE1 (0.44) | KDM1AKDM1BDGAT1BACE1CTSD | |
| SCHEMBL24698740 | 0.83 | KDM1A (0.39) | KDM1AKDM1BDGAT1BACE1CTSD | |
| SCHEMBL30016263 | 0.83 | KDM1A (0.39) | KDM1AKDM1BDGAT1BACE1CTSD | |
| Hydrochloric Acid SCHEMBL29134486 | 0.82 | KDM1A (0.38) | KDM1AKDM1BDGAT1BACE1CTSD | |
| SCHEMBL3849035 | 0.79 | BACE1 (0.45) | KDM1ABACE1CTSDBACE2 | |
| SCHEMBL29664671 | 0.79 | BACE1 (0.45) | KDM1ABACE1CTSDBACE2 | |
| Hydrochloric Acid SCHEMBL15914203 | 0.78 | BACE1 (0.44) | KDM1ABACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022037585-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-02-24 | — | — | WO | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| US-20210070708-A1 | Pharmaceutically Active Compounds | BERGENBIO ASA (NO) | 2021-03-11 | — | — | US | disclosed |
| CN-112047877-A | Novel amide compound and use thereof | 和记黄埔医药（上海）有限公司 | 2020-12-08 | — | — | CN | disclosed |
| WO-2020228823-A1 | NOVEL AMIDE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020228823-A1 | NOVEL AMIDE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2020-11-19 | — | — | WO | disclosed |
| US-10766861-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2020-09-08 | — | — | US | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10336702-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2019-07-02 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| WO-2011090935-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011090935-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LYN | KDM1A 1876/4885KDM1B 1397/4885DGAT1 2523/4885 |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | KDM1A 2124/4885KDM1B 1601/4885DGAT1 2622/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | KDM1A 1876/4885KDM1B 1397/4885DGAT1 2523/4885 |
| US-10336702-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | KDM1A 4460/4885KDM1B 4386/4885DGAT1 2612/4885 |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, RPS6KA5 | KDM1A 1323/4885KDM1B 1529/4885DGAT1 4104/4885 |
| US-20210070708-A1 | Pharmaceutically Active Compounds | UGT2B7, CYP3A5, UGT1A1 | KDM1A 4419/4885KDM1B 4366/4885DGAT1 2591/4885 |
| US-10766861-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | KDM1A 4419/4885KDM1B 4366/4885DGAT1 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.